Table 2.
A Selection of Ongoing Recruiting OV Clinical Trials
| Viral Species | Virus Name | Condition | Route of Administration | Co-therapy | Phase | ClinicalTrials. gov Identifier |
|---|---|---|---|---|---|---|
| Adenovirus | DNX-2401 | CNS cancer | intra-arterial | therapeutic conventional surgery | I | NCT0389656 |
| CNS cancer | i.t. | chemoradiotherapy | I | NCT03178032 | ||
| NSC-CRAd-Survivin-pk7 | CNS cancer | i.t. | surgery; chemoradiotherapy | I | NCT03072134 | |
| Ad5-yCD/mutTKSR39rep-ADP | NSCLC | i.t. | chemoradiotherapy; valacyclovir | I | NCT03029871 | |
| Ad5-yCD/mutTKSR39rep-hIL12 | pancreatic cancer | i.t. | 5-FC; chemotherapy | I | NCT03281382 | |
| prostate cancer | i.t. | radiation | I | NCT02555397 | ||
| DNX-2440 | CNS cancer | i.t. | – | I | NCT03714334 | |
| LOAd703 | pancreatic cancer | i.t. | gemcitabine; nab-paclitaxel | I/IIa | NCT02705196 | |
| pancreatic, ovarian, biliary, colorectal cancer | i.t. | chemotherapy | I/II | NCT03225989 | ||
| ADV/HSV-tk | NSCLC | i.t. | valacyclovir; pembrolizumab; SBRT | II | NCT03004183 | |
| ONCOS-102 | melanoma | i.t. | cyclophosphamide; pembrolizumab | I | NCT03003676 | |
| prostate cancer | i.t. | DCVac/Pca; cyclophosphamide | I/II | NCT03514836 | ||
| NG-350A | metastatic cancer; epithelial tumor | i.t./i.v. | – | I | NCT03852511 | |
| Enadenotucirev | rectal cancer | i.t. | capecitabine; radiotherapy | I | NCT03916510 | |
| ovarian cancer | i.t./i.p. | – | I | NCT02028117 | ||
| VCN-01 | head and neck cancer | i.t. | durvalumab | I | NCT03799744 | |
| Telomelysin (OBP-301) | esophageal cancer | i.t. | radiation | I | NCT03213054 | |
| Herpes virus | OH2 | solid tumor; gastrointestinal cancer | i.t. | HX 008 | I | NCT03866525 |
| rQNestin34.5v.2 | CNS cancer | i.t. | cyclophosphamide | I | NCT03152318 | |
| T-VEC | melanoma | i.t. | CD1c (BDCA-1); myeloid DCs | I | NCT03747744 | |
| peritoneal surface malignancies | i.p. | – | I | NCT03663712 | ||
| breast cancer | i.t. | paclitaxel | I/II | NCT02779855 | ||
| M032 | CNS cancer | i.t. | – | I | NCT02062827 | |
| G207 | CNS cancer | i.t. | radiotherapy | I | NCT02457845 | |
| Vaccinia virus | Pexa-Vec (JX-594) | colorectal cancer | i.v. | durvalumab; tremelimumab | I/II | NCT03206073 |
| HCC | i.t. | nivolumab | I/IIa | NCT03071094 | ||
| HCC | i.t. | sorafenib | III | NCT02562755 | ||
| metastatic tumor; advanced tumor | i.t. | ipilimumab | I | NCT02977156 | ||
| solid tumors; soft-tissue sarcoma; breast cancer | i.v. | cyclophosphamide | I/II | NCT02630368 | ||
| renal cell carcinoma | i.v. | REGN2810 | I | NCT03294083 | ||
| GL-ONC1 | ovarian cancer | i.p. | chemotherapy; bevacizumab | I/II | NCT02759588 | |
| TG6002 | CNS cancer | i.v. | 5-FC | I/II | NCT03294486 | |
| ASP9801 | solid tumors | i.t. | –- | I | NCT03954067 | |
| Poliovirus/rhinovirus | PVSRIPO | CNS cancer | i.t. | – | II | NCT02986178 |
| CNS cancer | i.t. | – | Ib | NCT03043391 | ||
| triple-negative breast cancer | i.t. | surgery | I | NCT03564782 | ||
| melanoma | i.t. | – | I | NCT03712358 | ||
| Measles virus | MV-NIS | multiple myeloma | i.t. | cyclophosphamide | II | NCT02192775 |
| ovarian, fallopian, peritoneal cancer | i.p. | paclitaxel; pegylated liposomal doxorubicin hydrochlorid | II | NCT02364713 | ||
| ovarian cancer | i.p. | mesenchymal stem cell transplantation | I/II | NCT02068794 | ||
| CNS cancer | i.t. | –- | I | NCT02700230 | ||
| VSV | VSV-IFNβ-NIS | solid tumor; HCC; NSCLC | i.v. | pembrolizumab | I | NCT03647163 |
| endometrial cancer | i.v. | – | I | NCT03120624 | ||
| Reovirus | plasma cell myeloma | i.v. | carfilzomib; dexamethasone; nivolumab | I | NCT03605719 | |
| multiple myeloma | i.v. | lenalidomide; pomalidomide | I | NCT03015922 | ||
| Coxsackie virus | CVA21 | NSCLC | i.v. | pembrolizumab | I | NCT02824965 |
VSV, vesicular stomatitis virus; HCC, hepatocellular carcinoma; CNS, central nervous system; NSCLC, non-small cell lung cancer; i.t., intratumoral; i.v., intravenous; i.p., intraperitoneal; 5-FC, 5-fluorocytosine; SBRT, stereotactic body radiation therapy.